SCHEMBL26224474

SCHEMBL26224474

CC(=O)Nc1cccc(CCCCCC(=O)C(C)C)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 1/20 0.48
NPSR1 Q6W5P4 1/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
RAB9A P51151 3/20 0.46
NPC1 O15118 2/20 0.46
LMNA P02545 1/20 0.45
TSHR P16473 2/20 0.45
HSD17B10 Q99714 2/20 0.45
S1PR1 P21453 4/20 0.45
S1PR4 O95977 2/20 0.45
S1PR3 Q99500 2/20 0.45
S1PR5 Q9H228 2/20 0.45
POLB P06746 2/20 0.44
NR4A1 P22736 1/20 0.44
ALDH1A1 P00352 2/20 0.44
CYP1A2 P05177 1/20 0.44
HDAC3 O15379 1/20 0.44
HDAC4 P56524 1/20 0.44
HDAC1 Q13547 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27064608 0.99 AOC3 (0.49) AOC3NPSR1MEN1KMT2ARAB9A
SCHEMBL25123144 0.95 LMNA (0.50) AOC3NPSR1MEN1KMT2ARAB9A
SCHEMBL26203920 0.90 S1PR1 (0.50) RAB9ANPC1LMNAS1PR1S1PR4
SCHEMBL26203927 0.88 SMN1; SMN2 (0.49) KMT2ARAB9ANPC1LMNATSHR
SCHEMBL5353446 0.85 MEN1 (0.63) AOC3NPSR1MEN1KMT2ARAB9A
SCHEMBL22526066 0.85 AOC3 (0.53) AOC3NPSR1MEN1KMT2ARAB9A
SCHEMBL26203918 0.84 SMN1; SMN2 (0.50) MEN1KMT2ARAB9ANPC1LMNA
SCHEMBL5106598 0.83 MEN1 (0.65) AOC3NPSR1MEN1KMT2ARAB9A
SCHEMBL22526185 0.83 AOC3 (0.49) AOC3NPSR1MEN1KMT2ARAB9A
SCHEMBL25122909 0.83 RAB9A (0.52) AOC3NPSR1MEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240016942-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-18 US disclosed
US-11746120-B2 Stat degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-09-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11746120-B2 Stat degraders and uses thereof STAT4, STAT1, STAT3 AOC3 3582/4885NPSR1 1322/4885MEN1 3280/4885
US-20240016942-A1 STAT DEGRADERS AND USES THEREOF STAT4, STAT1, STAT3 AOC3 3582/4885NPSR1 1322/4885MEN1 3280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.